



## SEQUENCE LISTING

<110> UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

<120> TAT AS AN IMMUNOGEN

<130> 050229-0444

<140> 10/506,408

<141> 2005-06-22

<150> PCT/US03/05806

<151> 2003-02-27

<150> US 60/361,043

<151> 2002-03-01

<160> 3

<170> PatentIn version 3.4

<210> 1

<211> 72

<212> PRT

<213> HIV

<400> 1

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser  
1 5 10 15

Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe  
20 25 30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly  
35 40 45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr  
50 55 60

His Gln Ala Ser Leu Ser Lys Gln  
65 70

<210> 2

<211> 86

<212> PRT

<213> HIV

<400> 2

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser  
1 5 10 15

Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe  
 20 25 30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly  
 35 40 45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr  
 50 55 60

His Gln Ala Ser Leu Ser Lys Gln Pro Thr Ser Gln Pro Arg Gly Asp  
 65 70 75 80

Pro Thr Gly Pro Lys Glu  
 85

<210> 3  
 <211> 86  
 <212> PRT  
 <213> HIV

<220>  
 <221> MUTATION  
 <222> (22)..(22)  
 <223> Cys 22 SUBSTITUTED FOR Gly

<400> 3

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser  
 1 5 10 15

Gln Pro Lys Thr Ala Cys Thr Asn Gly Tyr Cys Lys Lys Cys Cys Phe  
 20 25 30

His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly  
 35 40 45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr  
 50 55 60

His Gln Ala Ser Leu Ser Lys Gln Pro Thr Ser Gln Pro Arg Gly Asp  
 65 70 75 80

Pro Thr Gly Pro Lys Glu  
 85